Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$77.41 – $110.40
6% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $162.2M | $85.8M | $270.0M | $229.8M | $196.3M | $158.2M | $174.9M | $221.3M |
| Cost of revenue | $35.9M | $5.2M | $13.7M | $16.4M | $13.6M | $9.6M | $8.2M | $12.3M |
| Gross profit | $126.3M | $80.6M | $256.2M | $213.4M | $182.7M | $148.5M | $166.7M | $209.1M |
| Gross margin | 77.9% | 93.9% | 94.9% | 92.8% | 93.1% | 93.9% | 95.3% | 94.5% |
| R&D | $74.0M | $50.6M | $53.8M | $72.2M | $83.4M | $99.3M | $103.5M | $95.2M |
| Operating income | −$14.1M | −$17.5M | $155.9M | $92.4M | $44.1M | −$3.8M | $6.5M | $40.3M |
| EBITDA | −$9.5M | −$11.7M | $155.9M | $104.1M | $52.1M | $4.5M | $21.2M | $48.3M |
| Net income | −$5.5M | −$9.2M | $137.3M | $92.9M | $49.4M | $1.1M | $26.1M | $75.0M |
| Net margin | -3.4% | -10.7% | 50.8% | 40.4% | 25.1% | 0.7% | 14.9% | 33.9% |
| EPS (diluted) | -0.30 | -0.50 | 7.49 | 5.13 | 2.73 | 0.06 | 1.49 | 4.30 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $205M | $2.04 | $1.20–$2.96 | 1 |
| 2027 | $277M | $5.13 | $3.03–$7.47 | 1 |
| 2028 | $386M | $10.47 | $6.19–$15.24 | 1 |
| 2029 | $407M | $11.60 | $6.85–$16.88 | 1 |
Forward consensus · source: Financial Modeling Prep
PHARMA MAR SA NEW
No one on the platform currently holds PHMMF.
No tracked institution reports a position in PHMMF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-06-25 | $0.8000 | 2025-06-27 |
| Execution date | Ratio |
|---|---|
| 2020-07-28 | 1-for-12reverse |
No one on the platform has traded PHMMF yet.
| $1.8B |
| — |
| IUSDFAS ONE Corporation | $14.00 | +0.00% | $998M | — |
| MEDGFMedacta Group S.A. | $83.91 | +0.00% | $1.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 71.0× earnings vs its 26.3× historical median P/E.
Fair value ≈ $29.49 · price $79.49 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.